•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Nasdaq Eyes Another Triple-Digit Gain as Tech Continues Higher
Are Consumer Discretionary Stocks Lagging Marriott International (MAR) This Year?
Why Investors Need to Take Advantage of These 2 Consumer Discretionary Stocks Now
Top 3 Consumer Stocks You May Want To Dump In Q4
Marriott International (MAR) Reports Next Week: Wall Street Expects Earnings Growth
Marriott International (MAR) Just Flashed Golden Cross Signal: Do You Buy?
The Marriott Vacation Clubs® and Topeka Collaborate to Launch Moon Crush "Sunshine Live," a New Destination Music Weekend
Will Marriott (MAR) Beat Estimates Again in Its Next Earnings Report?
These 2 Consumer Discretionary Stocks Could Beat Earnings: Why They Should Be on Your Radar
Revisiting Former Stock Picks Marriott, Logitech, Harmony Biosciences
Marriott International, Inc. $MAR Position Lifted by SteelPeak Wealth LLC
3,511 Shares of Marriott International, Inc. $MAR Bought by First Citizens Bank & Trust Co.
Marriott International, Inc. (NASDAQ:MAR) Stock Rated “Moderate Buy” by Sell-Side Analysts
Marriott International Announces Release Date For Third Quarter 2026 Earnings
The Rise of Place: Marriott International Reveals Asia Pacific's Future of Food
THE RITZ-CARLTON NAPLES, TIBURÓN REVEALS TRANSFORMED RESORT AND DYNAMIC CULINARY CONCEPTS
Lisata subsidiary Marea treats first patient in MAR002 acromegaly trial
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
Forget Inflation: Funflation Is Here and These ETFs Are Riding on It
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026